How to buy Clarity Pharmaceuticals (CU6) shares
Learn how to easily invest in Clarity Pharmaceuticals shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Clarity Pharmaceuticals is a biotechnology business based in Australia. Clarity Pharmaceuticals shares (CU6) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Clarity Pharmaceuticals has a trailing 12-month revenue of around $3.2 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Clarity Pharmaceuticals
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Clarity Pharmaceuticals. Find the share by name or ticker symbol: CU6. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Clarity Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Clarity Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Clarity Pharmaceuticals stock price (ASX:CU6)Use our graph to track the performance of CU6 stocks over time.
Clarity Pharmaceuticals shares at a glance
|52-week range||$0.6975 - $1.71|
|50-day moving average||$0.8392|
|200-day moving average||$1.045|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.058|
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Clarity Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Clarity Pharmaceuticals price performance over time
|1 week (2022-01-17)||-8.57%|
|1 month (2021-12-24)||6.67%|
|3 months (2021-10-22)||-29.20%|
Clarity Pharmaceuticals financials
|Revenue TTM||$3.2 million|
|Gross profit TTM||$3.2 million|
|Return on assets TTM||-40.63%|
|Return on equity TTM||-71.89%|
|Market capitalisation||$215.3 million|
TTM: trailing 12 months
Clarity Pharmaceuticals share dividends
We're not expecting Clarity Pharmaceuticals to pay a dividend over the next 12 months.
Clarity Pharmaceuticals overview
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Stocks similar to Clarity Pharmaceuticals
Clarity Pharmaceuticals in the news
Frequently asked questions
More guides on Finder
Ethereum price continues downward spiral while a major competitor posts gains of 50%
The total market cap of the crypto sector has dropped by more than 30% over the last couple of months as reflected in ETH's price movements.
Bitcoin’s price stagnation a cause for concern as key indicators continue to dip
Some of Bitcoin’s core fundamentals suggest that more price drops may be incoming for the digital asset in the near term.
3 cheap overseas holidays you can take now that QLD borders are open
With self-quarantine measures scrapped, travelling overseas from Queensland just got a whole lot easier.
Telstra 1-day sale: $400 off Samsung Z Fold 3, new S21 FE and more
You have 24 hours to grab Telstra's latest phone deals.
How to register a positive RAT test in NSW
The NSW government now requires you to register your positive rapid antigen test result.
Where to bulk buy rapid antigen tests online
Restock your supply of rapid antigen home testing kits online at any of these reliable stores and help to stop the spread of COVID-19.
Finder appoints Chief Legal Officer and Global VP, Product Design
Finder has appointed David Chen as Chief Legal Officer and David Meier as Global Vice President (VP) of Product Design, as the global fintech continues to roll out new products and services, focusing on Web 3.0.
Apple MagSafe Battery review: It’s all about the convenience
The Apple MagSafe battery makes it very easy to keep even the worst iPhones charged, especially if you own an iPhone 12 Mini or iPhone 13 Mini.
American Express Corporate Platinum Card
With a 300,000 bonus Membership Rewards points offer, lounge access and management tools, is this Amex account right for your company?
Where to buy N95 masks in Australia
An N95 mask is one of the best ways to protect yourself and others against COVID-19. Here's where to buy N95 face masks in Australia.
Ask an Expert